Table 2. Adverse events (grade 3–4) in both groups.
| Adverse events | Low group (n=22) | High group (n=22) | P value |
|---|---|---|---|
| Death due to an adverse event | 0 | 0 | |
| Hematologic adverse event (≥ grade 3) | 16 (72.7) | 11 (50.0) | 0.11 |
| Neutropenia | 8 (36.4) | 6 (27.3) | 0.54 |
| Leukopenia | 13 (59.1) | 9 (40.9) | 0.37 |
| Thrombocytopenia | 4 (18.2) | 3 (13.6) | >0.99 |
| Anemia | 7 (31.8) | 3 (13.6) | 0.28 |
| Nonhematologic adverse event (grade 3–4) | 11 (50.0) | 15 (68.2) | 0.18 |
| Occurring in >3% of patients | |||
| Cholangitis | 5 (22.7) | 10 (45.5) | 0.20 |
| Febrile neutropenia | 0 | 3 (13.6) | 0.23 |
| Appetite loss | 2 (9.1) | 2 (9.1) | >0.99 |
| Fatigue | 2 (9.1) | 0 | 0.49 |
| Diarrhea | 1 (4.5) | 0 | >0.99 |
| Liver abscess | 1 (4.5) | 0 | >0.99 |
| Nausea/vomiting | 0 | 1 (4.5) | >0.99 |
Data are presented as or n (%). Low group included patients with an eGFR lower than the median eGFR at baseline, and high group included patients with an eGFR higher than the median eGFR at baseline. eGFR, estimated glomerular filtration rate.